Picornavirus Pico + RNA = Picorna

Genome is an mRNA. (+ sense) Naked genome is sufficient for infection. Virion is a naked, small (25 to 30 nm) icosahedral capsid enclosing a single-stranded positive RNA genome. Enteroviruses are resistant to pH 3 to pH 9, detergents, mild sewage treatment, and heat. Rhinoviruses are labile at acidic pH; optimum growth temperature is 33° C. Genome is an mRNA. (+ sense) Naked genome is sufficient for infection. Virus replicates in cytoplasm. Viral RNA is translated into polyprotein, which is then cleaved into enzymatic and structural proteins. Most viruses are cytolytic Box 56-2. Unique Properties of Human Picornaviruses

Picornaviridae Enterovirus Poliovirus types 1, 2, and 3 Coxsackie A virus types 1 to 22 and 24 Coxsackie B virus types 1 to 6 Echovirus (ECHO virus) types 1 - 9, 11 - 27, 29 - 34 Enterovirus 68 to 71 and 73 to …. Parechovirus (formerly echovirus 22,23) Kobuvirus: Aichi virus and Ljungan virus Hepatovirus -Hepatitis A virus Rhinovirus types 1 to 100+ Animal viruses: Cardiovirus Aphthovirus …. Body_ID: B056001

eIF4G cleaved  cellular protein synthesis is shut off

Kozak sequence (NNNPuNNAUGG ) The initiation AUG codon in the polio virus open reading frame is preceded by eight other AUGs. RCCAUGG RYYAUGG (R = purine, Y = pyrimidine);

Disease Mechanisms of Picornaviruses Enteroviruses enter via the oropharynx, intestinal mucosa, or upper respiratory tract and infect the underlying lymphatic tissue; rhinoviruses are restricted to the upper respiratory tract In the absence of serum antibody, enterovirus spreads by viremia to cells of a receptor-bearing target tissue Different picornaviruses bind to different receptors, many of which are members of the immunoglobulin superfamily (i.e., ICAM-1) The infected target tissue determines the subsequent disease Viral, rather than immune, pathologic effects are usually responsible for causing disease symptoms The secretory antibody response is transistory but can prevent the initiation of infection Serum antibody blocks viremic spread to target tissue, preventing symptoms Enterovirus is shed in feces for long periods Infection is often asymptomatic or causes mild, flulike or upper respiratory tract disease Body_ID: B056003

Epidemiology of Enterovirus Infections Disease/Viral Factors Nature of disease correlates with specific enterovirus and age of person Infection often asymptomatic, with viral shedding Virion resistant to environmental conditions (detergents, acid, drying, mild sewage treatment, and heat) Transmission Fecal-oral route: poor hygiene, dirty diapers (especially in daycare settings) Ingestion via contaminated food and water Contact with infected hands and fomites Inhalation of infectious aerosols Body_ID: B056004 Body_ID: PB056004

Who Is at Risk? Modes of Control Young children: at risk for polio (asymptomatic or mild disease) Older children and adults: at risk for polio (asymptomatic to paralytic disease) Newborns and neonates: at highest risk for serious coxsackievirus and enterovirus disease Geography/Season Viruses have worldwide distribution; wild-type polio virtually eradicated in developed countries because of vaccination programs Disease more common in summer Modes of Control For polio, live oral polio vaccine (trivalent OPV) or inactivated trivalent polio vaccine (IPV) is administered For other enteroviruses, no vaccine; good hygiene limits spread Body_ID: B056004 Body_ID: PB056004

Poliovirus infection Asymptomatic illness results if the viral infection is limited to the oropharynx and the gut. At least 90% of poliovirus infections are asymptomatic. Abortive poliomyelitis, the minor illness, is a nonspecific febrile illness occurring in approximately 5% of infected people. Fever, headache, malaise, sore throat, and vomiting occur in such people within 3 to 4 days of exposure. Nonparalytic poliomyelitis or aseptic meningitis occurs in 1% to 2% of patients with poliovirus infections. In this disease, the virus progresses into the central nervous system and the meninges, causing back pain and muscle spasms in addition to the symptoms of the minor illness.

Paralytic polio, the major illness, occurs in 0. 1% to 2 Paralytic polio, the major illness, occurs in 0.1% to 2.0% of persons with poliovirus infections and is the most severe outcome. It appears 3 to 4 days after the minor illness has subsided, thereby producing a biphasic illness. In this disease, the virus spreads from the blood to the anterior horn cells of the spinal cord and to the motor cortex of the brain. The severity of paralysis is determined by the extent of the neuronal infection and by which neurons are affected. Spinal paralysis may involve one or more limbs, whereas bulbar (cranial) paralysis may involve a combination of cranial nerves and even the medullary respiratory center. Paralytic poliomyelitis is characterized by an asymmetrical flaccid paralysis with no sensory loss. Poliovirus type 1 is responsible for 85% of the cases of paralytic polio. Reversion of the attenuated vaccine virus types 2 and 3 to virulence can cause vaccine-associated disease.

Coxsackievirus and Echovirus Infections

Herpangina Type A 1-10 Type B 1-5 Echoviruses Mostly in children; epidemicin summer months Abrupt fever, sore throat, anorexia, abdominal pain and vesicles on soft palate, pharinx and tonsills

Hand-foot-and-mouth disease Coxsackie A16, 4, 5, 10

Myocardial and pericardial infections Coxsackie B, echovirus Sudden onset Diabetes: Coxsackie B 4

Viral (aseptic) meningitis Coxsackie A, B Echovirus Summer and fall

Fever, rash, and common coldlike symptoms Summer minor illnes: Rubelliform rush on face, neck and chest Accompanied by fever No distinctive feature Short duration

Plerodynia Coxsackie B Sudden chest pain, fever, malaise (Abdominal or testicular pain)

Laboratory Diagnosis CSF findings Culture Molecular and serological methods

Treatment and Prevention Vaccine available only for Polio

Rhinoviruses Advantages and Disadvantages of Polio Vaccines Epidemiology of Rhinovirus Infections Disease/Viral Factors Virion is resistant to drying and detergents Multiple serotypes preclude prior immunity Replication occurs at optimum temperature of 33° C and cooler temperatures Transmission Direct contact via infected hands and fomites Inhalation of infectious droplets Who Is at Risk? People of all ages Geography/Season Virus found worldwide Disease more common in early autumn and late spring Modes of Control Washing hands and disinfecting contaminated objects help prevent spread Vaccine Advantages Disadvantages Live (oral polio vaccine) Effective Lifelong immunity Induction of secretory antibody response similar to that of natural infection Spread of attenuated virus circulating to contacts promotes indirect immunization (herd immunity) Inexpensive and easy to administer No need for repeated booster vaccine Risk of vaccine-associated poliomyelitis in vaccine recipients or contacts; spread of vaccine to contacts without their consent Not safe for administration to immunodeficient patients Inactivated polio vaccine Effective Good stability during transport and in storage Safe administration in immunodeficient patients No risk of vaccine-related disease Lack of induction of secretory antibody Booster vaccine needed for lifelong immunity Requires sterile syringes and needles Injection more painful than oral administration Higher community immunization levels needed than with live vaccine Vaccine Advantages Disadvantages Live (oral polio vaccine) Effective Lifelong immunity Induction of secretory antibody response similar to that of natural infection Spread of attenuated virus circulating to contacts promotes indirect immunization (herd immunity) Inexpensive and easy to administer No need for repeated booster vaccine Risk of vaccine-associated poliomyelitis in vaccine recipients or contacts; spread of vaccine to contacts without their consent Not safe for administration to immunodeficient patients Inactivated polio vaccine Effective Good stability during transport and in storage Safe administration in immunodeficient patients No risk of vaccine-related disease Lack of induction of secretory antibody Booster vaccine needed for lifelong immunity Requires sterile syringes and needles Injection more painful than oral administration Higher community immunization levels needed than with live vaccine page page